Day: December 8, 2023

Regulated information – Brussels, Paris, Vienna, 8 December 2023 – 18:00 pm (CET)Dexia and BAWAG Group sign a sale and purchase agreement concerning the last remaining leasing activities of the Dexia Group Dexia and BAWAG Group today announce that they have signed a sale and purchase agreement allowing BAWAG Group to buy Dexia Crédit Local’s five non-regulated leasing entities: DCL Evolution, Alsatram, Dexiarail, as well as Dexia Flobail and Dexia CLF Régions Bail, both renamed Dexia FB France and Dexia RB France, following the withdrawal of their finance company authorisations, which was approved by the French Autorité de Contrôle Prudentiel et de Résolution (ACPR) on 27 October 2023 and took effect on the same date. This transaction will enable BAWAG Group to refinance a roughly EUR 750 million leasing portfolio from Dexia Crédit...

Please see the attached Press releaseAttachment20231208 v2 LS GIG MOU Press-release

In November 2023, Bigbank’s growth continued. Both the deposit portfolio and the loan portfolio grew, while the profit was at a good level. In deposits, the savings deposit portfolio showed strong growth, which grew in all markets. In Estonia, Finland, Germany, Austria, and the Netherlands, we offer savings deposit interests at the top of the market, and the rapidly increasing number of customers shows interest in this product and growing trust in Bigbank. The volume of term deposits increased only marginally and remained at the level of EUR 0.9 billion. In terms of loans, the home loan portfolio grew the most, the consumer loan portfolio to a lesser extent. A slight decrease occurred in the portfolio of business loans. All in all, receivables from customers increased to 1.65 billion euros. A certain decline in the quality of the...

Innofactor Plc Announcement 8.12.2023          Innofactor Plc: Share Repurchase 8.12.2023       In the Helsinki Stock Exchange         Trade date 8.12.2023  Bourse trade Buy  Share IFA1V  Amount 4,400 SharesAverage price/ share 1.1700 EURTotal cost 5,148.00 EUR          Innofactor Plc now holds a total of 580 029 sharesincluding the shares repurchased on 8.12.2023            On behalf of Innofactor Plc         Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       Additional information:    Sami Ensio, CEO    Innofactor Plc    Tel. +358 50 584 2029    sami.ensio@innofactor.com         www.innofactor.com       AttachmentInnofactor_8.12_trades

PRESS RELEASE Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software  Wolters Kluwer CCH Tagetik AI-based financial planning solution empowers finance professionals to make faster and better-informed decisions.  New York – Dec. 8, 2023 – Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that it has been recognized as a Leader in the 2023 Gartner Magic Quadrant for Financial Planning Software. Earlier this month, Wolters Kluwer also received recognition as a Leader in the Gartner Magic Quadrant for Financial Close and Consolidation Software.  CCH Tagetik Budgeting, Planning and Forecasting software is Wolters Kluwer’s AI-based, enterprise-wide planning solution, which helps global companies facilitate strategic, financial,...

Disclosure of total number of voting rights andnumber of shares forming the capitalas of November 30, 2023 CLICHY – December 08, 2023 Article L 233-8-II of the French “Code de Commerce” and Article 223-16 of the General Regulations of the French “Autorité des Marchés Financiers”. As of November 30, 2023, the total number of issued shares of SOCIÉTÉ BIC is 43,952,226 shares, representing:64,202,124 voting rights, 62,104,700 voting rights excluding shares without voting rightsABOUT BIC A world leader in stationery, lighters and shavers, BIC brings simplicity and joy to everyday Life. For more than 75 years, the Company has honored the tradition of providing high-quality, affordable, essential products to consumers everywhere. Through this unwavering dedication, BIC has become one of the most recognized brands and is a trademark registered...

Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2 Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2 These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. A statistically significant and clinically meaningful improvement in overall survival (OS), a secondary endpoint, was...

BONDUELLE Head office: “La Woestyne” – 59173 Renescure – FranceBonduelle a French S.C.A (Partnership limited by Shares) with a capital of 57 102 699,50 eurosRegistered under number : 447 250 044 ( Dunkerque Commercial and Companies Register) INFORMATION REGARDING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE COMPANY’S SHARE CAPITAL POST-MERGER SHARE CAPITAL OF LA PLAINE SA – BONDUELLE SCA ARTICLE 223-16 OF THE GENERAL REGULATION OF THE FINANCIAL MARKET AUTHORITYDate of the latest information Total number of shares forming capital Number of voting rights08.12.2023 (0h00 – Paris)32 630 114Theoretical Total52 254 729 Actual Total*51 672 037*Actual Total = total number of voting rights attached to the number of shares – shares without voting rightsAttachmentPost...

Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1 The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.1 The inavolisib combination...

CASINO, GUICHARD-PERRACHON Société anonyme au capital de 165 892 131,90 €Siège social : 1, Cours Antoine Guichard42000 Saint-Etienne554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de voteet d’actions composant le capital socialau 30 novembre 2023 (article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)Nombre d’actions composant le capital Nombre total de droits de vote Nombre total de droits de vote exerçables en assemblée générale108 426 230  155 602 629  155 062 537* * ** Fait le 8 décembre 2023 à 17h30AttachmentCasino_Nombre de droits de vote et d’actions au 30-11-2023 – Communiqué